Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region
High drug development costs from increasingly complex products have pushed pharma companies to accelerate timelines as much as possible, creating a “race to market” of sorts. But scaling up too quickly has its risks — risks that the right CDMO partner can help mitigate.
Watch Thermo Fisher Scientific’s on-demand webinar, “Navigating a smarter race to market for oral solid-dose products” to learn: